Welcome to the Solutions for Celiac website.
This NIH-funded clinical research study has been designed to assess the drink-based study medication latiglutenase and, in conjunction with a gluten-free diet, its ability to relieve common symptoms suffered by celiac disease patients typically experienced after accidental gluten exposure.
What to Expect
Latiglutenase is a combination of two enzymes that target and degrade gluten proteins in the stomach, rendering them inactive and less likely to cause the symptoms and intestinal damage associated with celiac disease.
The study medication is provided in powder form that, when mixed with a flavor packet in water, produces a clear liquid to be consumed with a meal.
Check if you pre-qualify online by clicking one of the “See if You Qualify” links. If qualified, your first appointment will involve a blood test to confirm if you are seropositive for celiac disease - meaning that your blood contains a minimal level of circulating antibodies to gluten.
Make 6 clinic visits over approximately 26 weeks
Report your daily celiac disease symptoms online
Complete study-related medical assessments
Maintain your gluten-free diet
Less than 5 times a month, eat a study-provided snack that is either gluten-free or gluten-containing (to simulate accidental gluten exposure)
Study medication and study-related tests and procedures at no cost to you
Transportation and parking reimbursement may be provided
Your voluntary participation contributes data that is anonymous and confidential.
After the study is completed, data from all participants will be analyzed by the study team to determine if the study medication improves symptoms of accidental gluten exposure compared to placebo.